Table 1.
Donors | Dose | Recipients | Site | n | Figure |
---|---|---|---|---|---|
Islets from Ins2-CCL21 NOD mice | 1,000 IEQ | Spontaneously diabetic NOD mice | EFP | 4 | Fig. 5B (red) |
Islets from nontransgenic NOD mice | 1,000 IEQ | Spontaneously diabetic NOD mice | EFP | 1 | Fig. 5B (black) |
Islets from CCL21 transgenic (CCL21+) C57BL/6 mice | 1,000 IEQ | Chemically diabetic BALB/c mice | EFP | 13 | Supplementary Fig. 2D (red) |
Islets from CCL21− control C57BL/6 mice | 1,000 IEQ | Chemically diabetic BALB/c mice | EFP | 4 | Supplementary Fig. 2D (black) |
Islets from Ins2-CCL21 NOD mice | 500 IEQ | 7-week-old NOD-scid mice | Kidney capsule (KD) | 7 | Fig. 5C (red) |
Islets from nontransgenic NOD mice | 500 IEQ | 7-week-old NOD-scid mice | Kidney capsule (KD) | 6 | Fig. 5C (black) |
EFP, epididymal fat pad.